Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression

J. Van Goubergen, M. Peřina, F. Handle, E. Morales, A. Kremer, O. Schmidt, G. Kristiansen, MV. Cronauer, FR. Santer

. 2025 ; 19 (2) : 496-518. [pub] 20240911

Language English Country United States

Document type Journal Article

Grant support
FC/2020/01 Fondation Cancer
10.55776/P36187 Austrian Science Fund

In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. Androgen receptor splice variant-7 (ARV7) is clinically the most relevant and has a distinct 3' untranslated region (3'UTR) compared to the AR full-length variant, suggesting a unique post-transcriptional regulation. Here, we set out to evaluate the applicability of the ARV7 3'UTR as a therapy target. A common single nucleotide polymorphism, rs5918762, was found to affect the splicing rate and thus the expression of ARV7 in cellular models and patient specimens. Serine/arginine-rich splicing factor 9 (SRSF9) was found to bind to and increase the inclusion of the cryptic exon 3 of ARV7 during the splicing process in the alternative C allele of rs5918762. The dual specificity protein kinase CLK2 interferes with the activity of SRSF9 by regulating its expression. Inhibition of the Cdc2-like kinase (CLK) family by the small molecules cirtuvivint or lorecivivint results in the decreased expression of ARV7. Both inhibitors show potent anti-proliferative effects in enzalutamide-treated or -naive PC models. Thus, targeting aberrant alternative splicing at the 3'UTR of ARV7 by disturbing the CLK2/SRSF9 axis might be a valuable therapeutic approach in late stage, ARSI-resistant PC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010131
003      
CZ-PrNML
005      
20250429135141.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/1878-0261.13728 $2 doi
035    __
$a (PubMed)39258426
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Van Goubergen, Jasper $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Austria
245    10
$a Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression / $c J. Van Goubergen, M. Peřina, F. Handle, E. Morales, A. Kremer, O. Schmidt, G. Kristiansen, MV. Cronauer, FR. Santer
520    9_
$a In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. Androgen receptor splice variant-7 (ARV7) is clinically the most relevant and has a distinct 3' untranslated region (3'UTR) compared to the AR full-length variant, suggesting a unique post-transcriptional regulation. Here, we set out to evaluate the applicability of the ARV7 3'UTR as a therapy target. A common single nucleotide polymorphism, rs5918762, was found to affect the splicing rate and thus the expression of ARV7 in cellular models and patient specimens. Serine/arginine-rich splicing factor 9 (SRSF9) was found to bind to and increase the inclusion of the cryptic exon 3 of ARV7 during the splicing process in the alternative C allele of rs5918762. The dual specificity protein kinase CLK2 interferes with the activity of SRSF9 by regulating its expression. Inhibition of the Cdc2-like kinase (CLK) family by the small molecules cirtuvivint or lorecivivint results in the decreased expression of ARV7. Both inhibitors show potent anti-proliferative effects in enzalutamide-treated or -naive PC models. Thus, targeting aberrant alternative splicing at the 3'UTR of ARV7 by disturbing the CLK2/SRSF9 axis might be a valuable therapeutic approach in late stage, ARSI-resistant PC.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a serin-arginin sestřihové faktory $x metabolismus $x genetika $7 D000068103
650    12
$a nádory prostaty $x genetika $x metabolismus $x patologie $x farmakoterapie $7 D011471
650    12
$a tyrosinkinasy $x genetika $x metabolismus $7 D011505
650    12
$a androgenní receptory $x metabolismus $x genetika $7 D011944
650    12
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a protein-serin-threoninkinasy $x genetika $x metabolismus $x antagonisté a inhibitory $7 D017346
650    _2
$a alternativní sestřih $x genetika $x účinky léků $7 D017398
650    _2
$a sestřih RNA $x genetika $7 D012326
650    _2
$a 3' nepřekládaná oblast $x genetika $7 D020413
650    _2
$a jednonukleotidový polymorfismus $x genetika $7 D020641
650    _2
$a protein - isoformy $x genetika $x metabolismus $7 D020033
655    _2
$a časopisecké články $7 D016428
700    1_
$a Peřina, Miroslav $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Austria $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Czech Republic
700    1_
$a Handle, Florian $u Institute of Pathology, Neuropathology & Molecular Pathology, Medical University of Innsbruck, Austria
700    1_
$a Morales, Elisa $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Austria
700    1_
$a Kremer, Anika $u Institute of Pathology, University Hospital Bonn, Germany
700    1_
$a Schmidt, Oliver $u Institute of Cell Biology, Biocenter, Medical University of Innsbruck, Austria
700    1_
$a Kristiansen, Glen $u Institute of Pathology, University Hospital Bonn, Germany
700    1_
$a Cronauer, Marcus V $u Institute of Pathology, University Hospital Bonn, Germany
700    1_
$a Santer, Frédéric R $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Austria $1 https://orcid.org/0000000245916368
773    0_
$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 19, č. 2 (2025), s. 496-518
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39258426 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135137 $b ABA008
999    __
$a ok $b bmc $g 2311483 $s 1247212
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 19 $c 2 $d 496-518 $e 20240911 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
GRA    __
$a FC/2020/01 $p Fondation Cancer
GRA    __
$a 10.55776/P36187 $p Austrian Science Fund
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...